Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Apr 02, 2026
Why Commercial Vehicle Group (CVGI) Stock Surged +89% in the Last 30 Days

Why Commercial Vehicle Group (CVGI) Stock Surged +89% in the Last 30 Days

Key Takeaways

  • CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance.
  • Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
  • Major catalysts include Q4 adjusted EBITDA growth of 155.6% year-over-year (YoY), free cash flow of $34 million for 2025, and selection as wire harness supplier for Zoox autonomous vehicles.
  • 2026 guidance projects net sales of $660–$700 million and adjusted EBITDA of $24–$30 million, exceeding analyst expectations.
  • Global Electrical Systems segment showed 12.7% revenue growth and margin expansion amid industry demand softness.

Understanding Commercial Vehicle Group (CVGI) and Its Market Position

Commercial Vehicle Group, Inc. (CVGI) designs, engineers, and manufactures cab-related products and systems for the global commercial vehicle market. Its core business model spans three segments: Global Seating, Global Electrical Systems, and Trim Systems and Components, serving heavy-duty trucks, construction, agriculture, and emerging electric and autonomous vehicle sectors across North America, Europe, and Asia-Pacific.

From what I see, CVGI holds a competitive position as a diversified supplier with exposure to resilient electrical systems amid a shift toward electrification. The recent stock price movement aligns closely with its fundamentals, including operational efficiencies like lower-cost production in Morocco and Mexico, which boosted margins despite softer North American Class 8 truck demand.

CVGI Stock Price Performance: Breaking Down the Last 30 Days and Quarter

Over the last 30 days, CVGI stock climbed from around $1.80 to $3.41, marking a +89% gain. The movement was volatile and trend-driven, with a sharp rally post-Q4 earnings on March 10, peaking near $3.92 before recent pullbacks.

For the past quarter, shares advanced from approximately $1.51 to $3.41, delivering a +126% increase. Performance featured steady gains amid earnings anticipation, accelerated by results and guidance, though punctuated by intraday swings typical of small-cap industrials.

The Key Drivers Behind CVGI's +89% Rally in the Last 30 Days

The primary catalyst was CVGI's Q4 2025 earnings release on March 10, revealing revenue of $154.8 million, surpassing estimates by 5.2% despite a 5.2% YoY decline from softer demand. Adjusted EBITDA rose 155.6% YoY to $2.3 million, with gross margins expanding 190 basis points (bps). Shares jumped 24.5% immediately after, fueled by full-year free cash flow of $34 million and total debt reduction of $29.1 million.

Concurrent announcement of CVGI as a key low-voltage wire harness partner for Zoox's autonomous vehicles enhanced sentiment, highlighting growth in electrical systems. Analyst reiterations, including Buy ratings with $4 targets from Noble Financial and Barrington, supported the rally amid improved operational metrics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Powered CVGI Stock's +126% Gain Over the Past Quarter

The quarter's +126% surge stemmed from sustained operational improvements offsetting industry headwinds like reduced North American Class 8 truck production. Full-year 2025 revenue fell 10.3% to $649 million, but adjusted operating income held at $4.8 million, with SG&A (selling, general, and administrative expenses) down $4.8 million YoY.

Macro factors included resilient demand in electrical systems for electrification trends, with that segment up 12.7% in Q4. Institutional focus on cash generation—$34 million free cash flow—and debt paydown bolstered investor confidence. Cumulative impact from efficiency gains in low-cost facilities and positive guidance overshadowed revenue softness. One thing that stands out is how these efficiencies have positioned the company well for the year ahead.

Trending AI Robots: A Tool I Rely On for Trading Insights

In my own trading and research, I often turn to Tickeron’s Trending AI Robots page, which showcases the platform's top-performing AI-driven trading bots from among hundreds that analyze and trade thousands of tickers across various markets. These curated bots are selected based on recent performance metrics, relevance to current market trends, and strategy effectiveness, including short-term scalping, swing trading, or long-term trend following. Each bot displays key stats like win rate, average return, Sharpe ratio (a measure of risk-adjusted performance), and backtested results, allowing users to filter by timeframe, risk level, or asset class. Whether momentum-based or mean-reversion strategies, they provide transparent, data-backed insights. I’m watching this closely as it helps me integrate advanced automation into my approach.

CVGI Stock Outlook: Key Drivers and What to Watch Next

Investors should monitor Q1 2026 earnings for progress toward $660–$700 million full-year sales guidance and $24–$30 million adjusted EBITDA. Track Global Electrical Systems growth, including Zoox program ramps and electrification demand.

In my view, industry trends like commercial vehicle production recovery, aftermarket strength, and autonomous tech adoption remain key. Macro conditions, including interest rates affecting capex and supply chain dynamics, could influence sentiment. Strategic developments such as further debt reduction and potential M&A (mergers and acquisitions) warrant attention, alongside risks from demand volatility and equity issuance dilution. This is important because it could shape the stock's trajectory in the coming months.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.

Related Ticker: CVGI

CVGI's RSI Indicator ascending out of oversold territory

The RSI Oscillator for CVGI moved out of oversold territory on August 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 26 of the 30 cases the stock moved higher. This puts the odds of a move higher at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 62 cases where CVGI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Momentum Indicator moved above the 0 level on October 01, 2026. You may want to consider a long position or call options on CVGI as a result. In 76 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for CVGI just turned positive on August 26, 2026. Looking at past instances where CVGI's MACD turned positive, the stock continued to rise in 37 of 48 cases over the following month. The odds of a continued upward trend are 77%.

Following a +3.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVGI advanced for three days, in 189 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

CVGI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 50-day moving average for CVGI moved below the 200-day moving average on October 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVGI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for CVGI entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.884) is normal, around the industry mean (6.969). P/E Ratio (2.293) is within average values for comparable stocks, (71.549). Projected Growth (PEG Ratio) (1.184) is also within normal values, averaging (1.471). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.155) is also within normal values, averaging (49.084).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CVGI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVGI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

Notable companies

The most notable companies in this group are AutoZone (NYSE:AZO), Advance Auto Parts (NYSE:AAP), Goodyear Tire & Rubber Company (The) (NASDAQ:GT).

Industry description

OEM or Original Equipment Manufacturer of auto parts refers to the original producer of a vehicles components, and so OEM car parts are usually identical to the parts used in producing the vehicle in the first place. OEM parts tend to fit the specifications of a particular model, and their compatibility is often guaranteed by the automaker itself. OEM parts could be more expensive to buy (compared to other vendors’ products) when a consumer goes for replacement. However, increased competition from aftermarket parts/third-party vendors could, in some cases, keep EOM prices in check. The industry might progress further in adopting newer technologies like 3D printing to boost supply chain performance and quality. Aptiv PLC, Magna International Inc. and BorgWarner Inc. are major OEMs for autos.

Market Cap

The average market capitalization across the Auto Parts: OEM Industry is 4.89B. The market cap for tickers in the group ranges from 1.93K to 69.98B. ORLY holds the highest valuation in this group at 69.98B. The lowest valued company is CREVF at 1.93K.

High and low price notable news

The average weekly price growth across all stocks in the Auto Parts: OEM Industry was -0%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -8%. SES experienced the highest price growth at 66%, while GTEC experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Auto Parts: OEM Industry was 20%. For the same stocks of the Industry, the average monthly volume growth was 31% and the average quarterly volume growth was 9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 59
Price Growth Rating: 61
SMR Rating: 78
Profit Risk Rating: 88
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
CVGI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a supplier of cab related products and systems

Industry AutoPartsOEM

Industry
Trucks Or Construction Or Farm Machinery
Address
7800 Walton Parkway
Phone
+1 614 289-5360
Employees
6500
Web
https://www.cvgrp.com
Interact to see
Advertisement
United Therapeutics Corporation focuses on biotechnology innovations for chronic and life-threatening conditions, particularly in pulmonary diseases. The company's portfolio centers on treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), featuring products like Tyvaso (treprostinil inhalation solution), Orenitram (oral treprostinil), Remodulin, and Adcirca.
WVE stock plunged approximately -52% over the past 30 days, driven primarily by disappointing high-dose data from the Phase 1 INLIGHT trial of obesity candidate WVE-007 on March 26, which erased prior gains from positive initial results. Over the past quarter, shares declined around -61%, reflecting high volatility in biotech sentiment amid clinical trial outcomes and broader sector pressures on clinical-stage firms
KOD stock surged +39% over the past 30 days, driven primarily by positive Phase 3 GLOW2 trial results for Zenkuda in diabetic retinopathy. Over the past quarter, shares gained +36%, reflecting anticipation of clinical catalysts and a successful $184 million capital raise.
Roblox Corporation (RBLX) runs a platform where millions of users create and dive into immersive 3D experiences. The business centers on a virtual economy: users buy Robux for in-game items, and creators cash out through the developer exchange (DevEx) program. In the online gaming space, Roblox stands out as a metaverse pioneer, going up against the likes of Epic Games' Fortnite and newer AI-driven platforms. The fundamentals reflect impressive user growth—daily active users (DAUs) reached 144 million in Q4 2025, a 69% jump year-over-year—but ongoing net losses underscore the heavy spending on infrastructure, AI, and safety. From what I see, this tension between growth and profitability has fueled much of the recent volatility in RBLX shares, as investors weigh strong engagement against shrinking margins.
Megan Holdings Limited (MGN) is a Malaysia-based company focused on the development, construction, maintenance, and upgrade of aquaculture and agriculture farms, along with related services. At its core, the business provides end-to-end solutions for shrimp farms, from design and building hatcheries to ongoing maintenance. It operates mainly in Sabah, Malaysia, across segments like aquaculture/agriculture, industrial solutions such as smart technologies, and investments in marketable securities.
Megan Holdings Limited (MGN), based in Kuala Lumpur and founded in 2020, focuses on developing, constructing, maintaining, and upgrading aquaculture and agriculture farms in Malaysia. The company operates in three segments—aquaculture and agriculture, industrial solutions like supplying smart technologies and machinery rentals, and investments in marketable securities—carving out a niche in engineering and construction within the Industrials sector. Its subsidiary status under Star Sprite Limited adds a layer of operational stability.
Pony AI Inc. (PONY) stands out as a leading player in autonomous mobility, dedicated to bringing self-driving technology to commercial use. Founded in 2016 and based in Guangzhou, China, the company operates across China, the U.S., and other international markets, offering robotaxi services, robotruck logistics, and licensing for intelligent driving solutions. Its business model leans heavily on asset-light partnerships with original equipment manufacturers (OEMs), transportation network companies (TNCs), and logistics platforms.
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney and metabolic diseases. In my view, the company's core strength lies in its proprietary Maze Compass platform, which uses human genetics and variant functionalization to identify and advance therapies targeting genetically defined patient populations.
In my view, JPM stands out as the largest U.S. bank by assets and market capitalization, commanding leading market shares across key segments. It holds approximately 11.1% of U.S. retail deposits, 23.6% of credit card sales volume, 8.4% of global investment banking fees, 11.8% of markets revenue, and 10% of treasury services revenue. This diversified "universal banking model" spans consumer and community banking, commercial and investment banking, and asset and wealth management, generating resilient revenue streams.
In recent sessions, WMT has held steady around $124, pulling back from February highs near $134. From what I see, this resilience stands out as the stock has outperformed broader indices year-to-date, thanks to its defensive role in groceries and essentials. Shoppers are leaning toward value options, and consistent volumes show ongoing institutional support. The premium valuation reflects confidence in Walmart's omnichannel progress and market share gains. Even with macro headwinds, I view WMT as a portfolio staple during uncertain times.
I've been following ANTX, a biopharmaceutical company based in Menlo Park, California, that develops novel small molecule therapeutics from its proprietary boron chemistry platform. The focus is on underserved areas like infectious diseases, with the lead candidate epetraborole advancing in Phase 3 trials for non-tuberculous mycobacterial (NTM) lung disease and acute melioidosis. The pipeline also includes AN2-502998 for chronic Chagas disease in preclinical stages, along with programs in oncology.
Tilly's, Inc. (TLYS) operates as a specialty retailer specializing in casual apparel, footwear, accessories, and hardgoods aimed at young men, women, boys, and girls. The company focuses on branded fashion inspired by action sports, surf, and skate culture, offering products like tops, bottoms, swimwear, backpacks, hats, and sunglasses from well-known brands such as Vans and Hurley. With approximately 223 stores in malls and lifestyle centers, complemented by e-commerce through www.tillys.com, Tilly's effectively combines physical and digital sales channels.
NKE shares are tumbling approximately 11% in premarket trading on April 1, 2026, sliding to near nine-year lows after the previous close of $52.82. The primary catalyst is Nike's weak Q4 fiscal 2026 guidance: management projected a 2%–4% revenue decline, sharply missing analyst expectations of approximately 1.9% growth.
Aemetis, Inc. (AMTX) is a renewable natural gas and renewable fuels company focused on developing and commercializing low- and negative-carbon intensity products that replace petroleum-based fuels. The company operates through segments including California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. Its core business model centers on converting agricultural waste—such as dairy manure into biogas and corn/wood waste into ethanol—into high-value biofuels like renewable natural gas (RNG), ethanol, biodiesel, and sustainable aviation fuel precursors.
Silvaco Group, Inc. (SVCO) provides technology computer-aided design (TCAD) software, electronic design automation (EDA) software, and semiconductor intellectual property (SIP) solutions. The company helps semiconductor and photonics firms design, simulate, and optimize processes from atomic-level modeling to complex system-on-chip (SoC) development. Its business centers on licensing software tools and IP blocks, along with engineering services, targeting high-growth areas like AI, power devices, automotive, foundries, and 5G/6G mobile.
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
APTV shares are tumbling approximately 14% in premarket trading on April 1, 2026, representing one of the sharpest single-session losses in the stock's recent history. The primary catalyst is Aptiv's Board of Directors formally approving the long-anticipated spin-off of its Electrical Distribution Systems (EDS) business, now named Versigent, combined with the announcement of a $1.6 billion private offering of senior notes tied to the transaction.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.